Arvinas, Inc. reported second quarter 2026 financial results and provided a corporate update on August 4, 2026. The company announced the first-ever U.S. FDA approval of a PROTAC therapy, VEPPANU (vepdegestrant), for ER+/HER2- breast cancer, followed by an out-licensing agreement with Rigel Pharmaceuticals for global development and commercialization rights. Arvinas recognized $249.7 million in revenue for the quarter ended June 30, 2026, compared to $22.4 million in the prior year period, driven largely by deferred revenue recognition from the Pfizer collaboration and milestone payments related to VEPPANU approval. Cash, cash equivalents, and marketable securities stood at $567.9 million as of June 30, 2026. The company also highlighted progress across its pipeline, including Phase 1 trials for ARV-393, ARV-102, and ARV-027, preclinical data for HPK1 degrader ARV-6723, and dose escalation completion for KRAS G12D degrader ARV-806. Arvinas is a clinical-stage biotechnology company pioneering targeted protein degradation therapies using its PROTAC platform.

Arvinas, Inc. announced that its Chief Medical Officer, Noah Berkowitz, M.D., Ph.D., will depart from the company on July 3, 2026. The company has initiated a search for a replacement. Arvinas, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted protein degradation therapies.

Arvinas, Inc. received HSR Clearance for its license agreement with Rigel Pharmaceuticals, Inc. for VEPPANU (vepdegestrant) rights, resulting in an aggregate upfront payment of $70.0 million to Arvinas and Pfizer. The Company and Pfizer are also eligible for an additional $15.0 million upon completion of transition activities and up to $320.0 million in contingent milestone and royalty payments. Arvinas, Inc. is a biotechnology company focused on protein degradation technologies.